Pal Highlights Encouraging ORR With Cabozantinib Plus Atezolizumab in mCRPC

Ellie Leick
Published: Monday, Feb 24, 2020
Dr. Sumanta K. Pal

Sumanta K. Pal, MD
Phase Ib results from cohort 6 of the COSMIC-021 trial suggest that the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) has encouraging clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC), explained Sumanta K. Pal, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication